Paragraphs
STRONG ACCURACY AND OUTCOMES ACROSS ALL MAJOR INDICATORS
Selector Id
strong-accuracy
Selector Class
impact-control
A demonstrated 8.5% Mean Absolute Relative Difference (MARD)¹
Sensor adherence of +23hrs per day4,5
Fluorescence-based technology unaffected by ascorbic acid and acetaminophen²
A clinically meaningful A1C reduction across major studies1,6,7
Exceptional accuracy in the 40-60 mg/dL hypoglycemic range (86.5% within 15/15 YSI)³
Exceptional real-world time in target1
EXCEPTIONAL PERFORMANCE AND REAL-WORLD OUTCOMES
A1C Reduction
Overall A1C level
Precise
0.4%
From a baseline of 7.5%
Precise II
0.5%
From a baseline of 7.6%
Precision
0.3%
From a baseline of 7.8%
MARD
Overall %
11.1%
8.5%
9.6%
Adherence
Hours per day
+23.0
+23.4
+23.2
Time in target
Overall %
+59.9%
+57.6%
+59.0%
hypoglycemic detection
Overall %
70 mg/dl
81%
70 mg/dl
93%
70 mg/dl
95%
A1C Reduction
Overall A1C level
Precise
0.4%
From a baseline of 7.5%
MARD
Overall %
11.1%
Adherence
Hours per day
+23.0
Time in target
Overall %
+59.9%
hypoglycemic detection
Overall %
70 mg/dl
81%
A1C Reduction
Overall A1C level
Precise II
0.5%
From a baseline of 7.6%
MARD
Overall %
8.5%
Adherence
Hours per day
+23.4
Time in target
Overall %
+57.6%
hypoglycemic detection
Overall %
70 mg/dl
93%
A1C Reduction
Overall A1C level
Precise
0.3%
From a baseline of 7.8%
MARD
Overall %
9.6%
Adherence
Hours per day
+23.2
Time in target
Overall %
+59.0%
hypoglycemic detection
Overall %
70 mg/dl
95%
For more information on Eversense’s safety and performance, download
our Performance and Outcomes
Data Sheet.
Selector Class
product-sheet x-overflow
Selector Class
section-next
Selector Class
section-lists
Sub Description
The advanced sensor technology and under-the-skin placement help patients reach unprecedented levels of wear time, leading to improved clinical outcomes.